Evidence map›Paper›PMID 41127404›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025

Topical Application of miR-200b-3p by Poloxamer 407-Based Hydrogel Accelerates Diabetic Wound Healing.

Wan-Yu Lo, Cian-Huei Sin, Huang-Joe Wang

Abstract read
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wan-Yu LoDepartment of Food Science and Technology, Hungkuang University, Taichung, Taiwan.
Cian-Huei SinDepartment of Food Science and Technology, Hungkuang University, Taichung, Taiwan.
Huang-Joe WangDepartment of Medicine, Division of Cardiovascular Medicine, China Medical University Hospital, Taichung, Taiwan.ORCID 0000-0002-2940-3837

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic foot ulcers (DFUs) are refractory to healing owing to excessive oxidative stress, increased proinflammatory cytokines, accumulation of senescent cells, and impaired angiogenesis. Local injections of miR-146a-5p and miR-200b-3p have pro-healing properties in diabetic wounds but are unrealistic in clinical practice. We investigated whether the topical application of miR-146a-5p and miR-200b-3p using a poloxamer 407-based hydrogel accelerated diabetic wound healing in db/db diabetic mice. In addition, we compared these two miRNAs to select a better microRNA for further application in patients with DFUs. Methods: The wound was created using an 8-mm punch biopsy. One hundred microliters of poloxamer P407 hydrogel formulations (gel, gel+miR-negative control, gel+miR-146a-5p, and gel+miR-200b-3p) were topically applied to each wound, and the hydrogel was changed every two days. Skin samples were sent for real-time PCR, H&E staining, and immunohistochemical staining. Results: On the 14th day, the gel+miR-200b-3p group demonstrated the best wound healing performance compared with the other three groups, as supported by the reduced wound size and enhanced granulation tissue thickness. Mechanistic insights showed that gel+miR-200b-3p caused significant upregulation of Conclusion: Topical application of miR-200b-3p by poloxamer 407 hydrogel showed better results in accelerating diabetic wound healing than miR-146a-5p. These data suggest that topical miR-200b-3p formulation is an effective treatment approach for DFUs.

Indexed as

angiogenesisinflammationmicroRNA-146a-5pmicroRNA-200b-3poxidative stresspoloxamer 407 hydrogelsenescence

Identifiers

PMID41127404
PMCPMC12538303

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.